CN Patent

CN108048465A — 一种抑制PARP基因用于治疗乳腺癌的siRNA

Assigned to Individual · Expires 2018-05-18 · 8y expired

What this patent protects

本发明涉及乳腺癌治疗技术领域，特别涉及利用抑制PARP基因表达的siRNA来降低PARP基因的表达水平，通过在线软件设计3对针对PARP基因的siRNA，通过Real‑time PCR、Western Blot和MTT实验分别检测PARP mRNA表达水平降低、蛋白质表达水平降低和抑制乳腺癌细胞增长，表明该siRNAs能够高效抑制PARP基因的表达，为PARP抑制剂的研发提供理论基础。

USPTO Abstract

本发明涉及乳腺癌治疗技术领域，特别涉及利用抑制PARP基因表达的siRNA来降低PARP基因的表达水平，通过在线软件设计3对针对PARP基因的siRNA，通过Real‑time PCR、Western Blot和MTT实验分别检测PARP mRNA表达水平降低、蛋白质表达水平降低和抑制乳腺癌细胞增长，表明该siRNAs能够高效抑制PARP基因的表达，为PARP抑制剂的研发提供理论基础。

Drugs covered by this patent

rucaparib-camsylate (RUCAPARIB CAMSYLATE)

Patent Metadata

Patent number: CN108048465A
Jurisdiction: CN
Classification: —
Expires: 2018-05-18
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.